Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2020
(Exact name of registrant as specified in its charter)

 (State or other jurisdiction of incorporation) 

  (Commission File Number) 
  (I.R.S. Employer Identification No.)
  1000 Skokie Blvd., Suite 350, Wilmette, IL 
  (Address of principal executive offices)
  (Zip Code)


(847) 388-0349
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

  Title of each class
  Trading Symbol(s)
Name of each exchange on which registered
  Common Stock, $0.001 par value
The Nasdaq Stock Market LLC 
(Nasdaq Capital Market)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement
On January 13, 2020, Monopar Therapeutics Inc (“Monopar” or the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Agreement”) with JonesTrading Institutional Services LLC, as sales agent (“JonesTrading” or the “Agent”), pursuant to which Monopar may offer and sell, from time to time, through or to JonesTrading shares of Common Stock, par value $0.001 per share, of Monopar having an aggregate offering price of up to $19.7 million (the “Shares”).
The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-235791) filed by the Company with the Securities and Exchange Commission (the “SEC”) on January 3, 2020 and declared effective by the SEC on January 13, 2020, as supplemented by a prospectus supplement dated January 13, 2020 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of the Company’s Common Stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Monopar is not obligated to sell any Shares under the Agreement.
Upon delivery of a placement notice by Monopar and subject to the terms and conditions of the Agreement and such placement notice, JonesTrading may sell the Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act and will use commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq Capital Market, to sell the Shares from time to time.
The offering of Shares pursuant to the Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by JonesTrading or the Company, as permitted therein.
The Company has agreed to pay JonesTrading commissions for its services in acting as agent in the sale of the Shares in the amount of up to 3.0% of gross proceeds from the sale of the Shares pursuant to the Agreement. The Company has also agreed to provide JonesTrading with customary indemnification and contribution rights, in connection with entering into the Agreement.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The opinion of the Company’s counsel regarding the validity of the Shares that may be issued pursuant to the Agreement is also filed herewith as Exhibit 5.1.
Item 8.01 Other Events
On December 18, 2019, the Company entered into an Underwriting agreement with JonesTrading related to Monopar’s initial public offering of its Common Stock, which pursuant to 5(j) of the Underwriting agreement, requires a waiver from JonesTrading if the Company contracts to sell any Common Stock during the period of 180 days from December 18, 2019. JonesTrading provided such waiver in order to accommodate the execution of the Capital on DemandTM Sales Agreement with JonesTrading on January 13, 2020 and any sales of shares of our Common Stock under such agreement.
Item 9.01 Financial Statements and Exhibits
Exhibit No.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Monopar Therapeutics Inc.

/s/ Chandler D. Robinson
Name: Chandler D. Robinson  
Title:  Chief Executive Officer

Date: January 13, 2020